new glp-1 receptor agonists approved for clinical use. GLP-1 agonists are available GLP-1 Agonists For Obesity In
Description
Is weight loss a goal
Ten GLP-1RAs induced a significantly higher risk of vomiting than placebo: ITCA 650, CagriSema, orforglipron, efpeglenatide, tirzepatide, lixisenatide, semaglutide, liraglutide, exenatide, and dulaglutide (fig 8D)
30 , 61429 doi: in press (2016)
It offered more convenience and quickly gained traction
Gastrointestinal symptoms are the most frequently reported issues, with nausea being the most common
"Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study"
